AbbVie has announced the completion of a $9 billion debt issuance to finance its acquisition of Apogee Therapeutics. The funds will primarily be used for cash consideration to Apogee shareholders and associated fees. The acquisition emphasizes AbbVie's commitment to expanding its portfolio in innovative therapies.
Company Information
Company
AbbVie
About
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Don't miss AbbVie's next move
Get an email the moment AbbVie makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired Apogee Therapeutics?
Apogee Therapeutics was acquired by AbbVie. The deal was reported on August 19, 2026. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. AbbVie is publicly traded (ABBV).
When did AbbVie acquire Apogee Therapeutics?
AbbVie's acquisition of Apogee Therapeutics was reported on August 19, 2026. AbbVie has announced the completion of a $9 billion debt issuance to finance its acquisition of Apogee Therapeutics. The funds will primarily be used for cash consideration to Apogee shareholders and associated fees. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Apogee Therapeutics do?
Apogee Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative biologic therapies for inflammatory and immunology diseases. It is publicly traded (APGE), operating in research.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
